Cocrystal Pharma (COCP) Research & Development (2010 - 2026)
Cocrystal Pharma (COCP) posted Research & Development of $1.4 million for Q1 2026, down 15.32% sequentially from $1.6 million in Q4 2025, and up 0.81% YoY from $1.4 million in Q1 2025.
Cocrystal Pharma (COCP) Research & Development (2010 - 2026) Analysis & Trends
Cocrystal Pharma has reported Research & Development for 16 years, with the latest figure at $1.4 million in Q1 2026.
- Quarterly Research & Development rose 0.81% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (down 53.72% YoY) and the FY2025 annual result came in at $5.1 million, down 59.68% from the prior year.
- Research & Development eased to $1.4 million in Q1 2026 per COCP's latest filing, from $1.6 million in the prior quarter.
- Over five years, Research & Development peaked at $4.3 million in Q2 2024 and troughed at $954000.0 in Q3 2025.
- A 5-year average of $2.7 million and a median of $2.9 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development surged 83.94% in 2022, then slumped 73.96% in 2025.
- Over 5 years, Research & Development stood at $3.3 million in 2022, then gained by 29.81% to $4.3 million in 2023, then plunged by 52.26% to $2.0 million in 2024, then declined by 20.52% to $1.6 million in 2025, then fell by 15.32% to $1.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.4 million, $1.6 million, and $954000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 97.90 Mn |
| 10 | Cocrystal Pharma | 16.13 Mn | 13.81 Mn | - | 2.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.14 Mn |
| Mar 31, 2026 | 1.37 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Sep 30, 2025 | 954,000.00 |
| Jun 30, 2025 | 1.12 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Sep 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | 4.31 Mn |
| Mar 31, 2024 | 2.95 Mn |
| Dec 31, 2023 | 4.27 Mn |
| Sep 30, 2023 | 4.19 Mn |
| Jun 30, 2023 | 2.80 Mn |
| Mar 31, 2023 | 3.91 Mn |
| Dec 31, 2022 | 3.29 Mn |
| Sep 30, 2022 | 3.87 Mn |
| Jun 30, 2022 | 2.36 Mn |
| Mar 31, 2022 | 2.87 Mn |
| Dec 31, 2021 | 2.73 Mn |
| Sep 30, 2021 | 2.11 Mn |